Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy
Drug Resistance Updates · 2023-05 · 68 · 100939
DOI: 10.1016/j.drup.2023.100939 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Resistance Updates, 2023-05. Verfasst von Yujia Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Me…. Hauptthemen laut MEDLINE: Thyroid Neoplasms. Die Arbeit wurde bisher 92-mal zitiert (Crossref) und nennt 267 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Thyroid cancer is the most prevalent endocrine tumor and its incidence is fast-growing worldwide in recent years. Differentiated thyroid cancer (DTC) is the most common pathological subtype which is typically curable with surgery and Radioactive iodine (RAI) therapy (approximately 85%). Radioactive iodine is the first-line treatment for patients with metastatic Papillary Thyroid Cancer (PTC). However, 60% of patients with aggressive metastasis DTC developed resistance to RAI treatment and had a poor overall prognosis. The molecular mechanisms of RAI resistance include gene mutation and fusion, failure to transport RAI into the DTC cells, and interference with the tumor microenvironment (TME). However, it is unclear whether the above are the main drivers of the inability of patients with DTC to benefit from iodine therapy. With the development of new biological technologies, strategies that bolster RAI function include TKI-targeted therapy, DTC cell redifferentiation, and improved drug delivery via extracellular vesicles (EVs) have emerged. Despite some promising data and early success, overall survival was not prolonged in the majority of patients, and the disease continued to progress. It is still necessary to understand the genetic landscape and signaling pathways leading to iodine resistance and enhance the effectiveness and safety of the RAI sensitization approach. This review will summarize the mechanisms of RAI resistance, predictive biomarkers of RAI resistance, and the current RAI sensitization strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
- Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, China.
- Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China; Key Laboratory of Endocrine…
- Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, China; Otolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People's Hospital, Affiliated People…
Zitieren
APA
Liu, Y., Wang, J., Hu, X., Pan, Z., Xu, T., Xu, J., Jiang, L., Huang, P., Zhang, Y., & Ge, M. (2023). Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy. Drug Resistance Updates, 68, 100939. https://doi.org/10.1016/j.drup.2023.100939
Vancouver
Liu Y, Wang J, Hu X, Pan Z, Xu T, Xu J, et al. Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy. Drug Resistance Updates. 2023;68:100939. doi:10.1016/j.drup.2023.100939
BibTeX
@article{Liu2023,
author = {Liu, Yujia and Wang, Jiafeng and Hu, Xiaoping and Pan, Zongfu and Xu, Tong and Xu, Jiajie and Jiang, Liehao and Huang, Ping and Zhang, Yiwen and Ge, Minghua},
title = {Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy},
journal = {Drug Resistance Updates},
year = {2023},
volume = {68},
pages = {100939},
doi = {10.1016/j.drup.2023.100939}
}
EUVIMED